Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
95 hedge funds and large institutions have $721M invested in Aegerion Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 41 reducing their positions, and 53 closing their positions.
27% less funds holding
Funds holding: 131 → 95 (-36)
37% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 41
42% less capital invested
Capital invested by funds: $1.24B → $721M (-$516M)
50% less call options, than puts
Call options by funds: $23.1M | Put options by funds: $46M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
64% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$38.9M |
| 2 |
Millennium Management
New York
|
+$33.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.6M |
| 4 |
Goldman Sachs
New York
|
+$14.8M |
| 5 |
SCM
Scopia Capital Management
New York
|
+$8.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$35.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$29.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$27.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.4M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$18.1M |
AEGR Hedge Fund Activity: Q4 2014 in Review
95 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q4 2014, worth a combined $721M — down 42% from $1.24B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of AEGR and 19 opened new positions — a net loss of 34 holders — while 41 trimmed existing stakes and 26 added.
The largest buyer was Broadfin Capital, adding an estimated $38.9M. The largest seller was JP Morgan Chase, cutting an estimated $35.1M.
- 95 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q4 2014, down from 131 in Q3 2014.
- Funds reported $721M of Aegerion Pharmaceuticals stock for Q4 2014, down 42% quarter-over-quarter.
- 19 funds opened new Aegerion Pharmaceuticals positions in Q4 2014 and 53 closed out, a net change of -34 holders.
- The largest Aegerion Pharmaceuticals buyer in Q4 2014 was Broadfin Capital, an estimated $38.9M added.
- The largest Aegerion Pharmaceuticals seller in Q4 2014 was JP Morgan Chase, an estimated $35.1M sold.
Based on aggregated 13F filings for Q4 2014.